Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07426172

Role of Elevated Lactate Levels on Lipid and Carbohydrate Metabolism.

The purpose of this study is to investigate whether the elevated circulating lactate levels of individuals with metabolic syndrome are responsible for their reduced lipolysis and glucose tolerance. The investigators will conduct an intervention study in which blood lactate levels will be elevated via intravenous infusion of sodium lactate. State of the art metabolic assessment using stable isotopes and indirect calorimetry will be used to study alterations in fat and carbohydrate metabolism.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Facultad de Ciencias del Deporte

San Javier, Murcia, 30720, Spain

Location status: Recruiting

Location contact

Jesus Garcia Pallares, PhD

CONTACT

[email protected]

+34665505278

Jesus Garcia Pallares, PhD

SUB_INVESTIGATOR

About this study

Individuals with metabolic syndrome and insulin resistance exhibit higher resting lactate concentrations than age-matched counterparts without metabolic disease. Recent studies suggest that lactate is not just a by-product of accelerated glycolysis but a signaling molecule that could even affect gene expression. However, the role of lactate in carbohydrate and fat metabolism at rest and during exercise remains incompletely described.

In this study, the investigators will elevate blood lactate levels in metabolically healthy individuals to levels observed in individuals with metabolic syndrome while measuring fat and carbohydrate metabolism in a fasted state, during exercise, and in response to an oral glucose load (oral glucose tolerance test).

10 metabolically healthy (MH) and 10 metabolically impaired (MI) individuals matched for sex and physical activity will participate in the study. MH will undergo two trials: one with intravenous lactate infusion and the other with isovolumetric saline infusion. The MI group will undergo only the saline trial.

Each trial consists of a 150 min basal period, an exercise period, followed by a 2-hour oral glucose tolerance test (OGTT). During the test, the investigators will:

Measure insulin sensitivity during the OGTT (Matsuda Index). Measure fat and carbohydrate oxidation using indirect calorimetry. Use stable isotope infusion to measure glycerol and glucose turnover rates in plasma using [1,1,2,3,3 2H]-glycerol and [6-6 2H], [U, 13C] - glucose.

Collect blood samples of relevant hormones, metabolites, and cytokines.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women
  • >18 years of age
  • Women non-pregnant or taking contraceptive medication
  • Physically active according to WHO's guidelines
  • Metabolic syndrome as IDF 2009 criteria (Alberti et al., Circulation)
  • Written and verbal consent to participation

Exclusion criteria

  • Chronic illness that prevents them from exercising
  • Affected blood samples at screening, as assessed by the PI
  • Assessed as unsuitable by PI

Treatment and study plan

hyperlactacidemia

Other

Raise blood lactate in metabolically healthy individuals to the levels of individuals with metabolic syndrome

Saline (0.9%, sterile, for infusion)

Other

Saline infusion as a control treatment

Primary outcomes

  1. Lipolysis rate at rest, exercise and OGTT when blood lactate is elevated in MH individuals

    Time frame: through study completion, an average of 2 years

    Change in plasma [1,1,2,3,3 D] glycerol turnover rates

  2. Effect of Na-Lactate on glucose tolerance to an oral load

    Time frame: through study completion, an average of 2 years

    Change in plasma [6,6 D]-glucose turnover rate

Secondary outcomes

  1. Insulin sensitivity

    Time frame: through study completion, an average of 2 years

    The difference between groups and interventions in Matsuda ISI during the glucose tolerance test

  2. Indirect calorimetry

    Time frame: through study completion, an average of 2 years

    Changes in fat and carbohydrate oxidation during treatments in both groups.

  3. Blood sample-insulin

    Time frame: through study completion, an average of 2 years

    Insulin concentrations. Difference between interventions and groups

  4. Blood samples - glucose

    Time frame: through study completion, an average of 2 years

    Glucose concentrations. Difference between interventions and groups

  5. Blood samples - Free fatty acids

    Time frame: through study completion, an average of 2 years

    Free fatty acids concentration. Difference between interventions and groups

  6. Blood samples - Glycerol

    Time frame: through study completion, an average of 2 years

    Glycerol concentrations. Difference between interventions and groups

  7. Blood samples - Lactate

    Time frame: through study completion, an average of 2 years

    lactate concentrations. Difference between interventions and groups

  8. Blood tracer/tracee ratio of 13C/12C glucose

    Time frame: through study completion, an average of 2 years

    Tracer/tracee ratio measured by CGMS of 13C/12C glucose

  9. 13CO2 / 12CO2 in expired air

    Time frame: through study completion, an average of 2 years

    Analisys of 13CO2 / 12CO2 by IRMS

  10. Blood tracer to tracee ratio of D2 glucose / unlabeled glucose

    Time frame: through study completion, an average of 2 years

    Ratio of plasma D2 glucose / unlabeled glucose measured by GCMS

  11. Blood tracer to tracee ratio of D5 glycerol / unlabeled glycerol

    Time frame: through study completion, an average of 2 years

    Blood ratio of D5 glycerol / unlabeled glycerol measured with GCMS

Study contacts

Contact information is provided by the study sponsor or research team.

Jesus Garcia-Pallares, PhD

CONTACT

[email protected]

+34665505278

Ricardo MORA RODRIGUEZ, PhD

CONTACT

[email protected]

+34675424515

Sponsors and collaborators

Lead sponsor

Ricardo Mora

Other

Collaborators

  • University of Castilla-La Mancha

Registry information

Acronym: LACTMET

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 23, 2026
Registry last updated
Feb 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.